Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
MMRF Holds CoMMpass Collaborator Meetings at ASCO 2016
MMRF Holds CoMMpass Collaborator Meetings at ASCO 2016
On Saturday June 4 at ASCO, the MMRF Research Team met with our CoMMpass trial collaborators to discuss the current status of the trial and new directions for CoMMpass in the near future.
On Saturday June 4 at ASCO, the MMRF Research Team met with our CoMMpass trial collaborators to discuss the current status of the trial and new directions for CoMMpass in the near future. Those invited to the collaborator meetings included the Principle Investigators at each of the 64 active CoMMpass clinical sites, the CoMMpass Steering Committee, and also collaborators from our CoMMpass pharma consortium, representatives from Amgen, Takeda Oncology, Janssen, and Bristol Myers Squibb.
- The current enrollment status of CoMMpass: 982 patients enrolled, with 950 genomically profiled
- CoMMpass data: our 10th Interim Analysis will be released in July 2016
- The CoMMpass trial amendment
The CoMMpass amendment is a major effort to increase benefits brought to patents through the trial. In the amendment, which is now approved by a majority of CoMMpass sites, patients will be enrolled in the trial longer (now up to 8 years instead of 5 years); this is due to the fact that improved therapies for multiple myeloma have improved progression free survival. Also included in the amendment is the provision for CLIA-grade genomic sequencing for CoMMpass patients at the time of progression. Having samples sequenced in CLIA-grade lab means that the results of the sequencing will be reported to the patient’s doctor, who can discuss the results with the patient and use those results to help determine which therapy might be best suited for the patients disease at that time based on genomic alterations that are found. The doctor may even suggest that the patient apply for a clinical trial based on these results. This is part of the MMRF’s Precision Medicine Initiative, which aims at having patients receiving the right medicine at the right time to respond best to their current form of the disease.
The meetings ended with a focus on the CoMMpass data. With the release of this Interim Analysis, and following discussions from the CoMMpass Data Jamboree in April, researchers are busy using the data to look for new therapeutic targets in Multiple Myeloma and new correlations between clinical and genomic data, with an aim to bring new and more effective medicines to patients faster than ever before!
